OncoCyte (OCX) Competitors $2.70 +0.06 (+2.27%) As of 09:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCX vs. RZLT, ARCT, ADCT, RAPP, ORGO, SNDL, IVA, PHAT, AURA, and TRDAShould you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Rezolute (RZLT), Arcturus Therapeutics (ARCT), ADC Therapeutics (ADCT), Rapport Therapeutics (RAPP), Organogenesis (ORGO), SNDL (SNDL), Inventiva (IVA), Phathom Pharmaceuticals (PHAT), Aura Biosciences (AURA), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry. OncoCyte vs. Its Competitors Rezolute Arcturus Therapeutics ADC Therapeutics Rapport Therapeutics Organogenesis SNDL Inventiva Phathom Pharmaceuticals Aura Biosciences Entrada Therapeutics OncoCyte (NASDAQ:OCX) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Is OCX or RZLT more profitable? Rezolute has a net margin of 0.00% compared to OncoCyte's net margin of -6,122.29%. Rezolute's return on equity of -70.27% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets OncoCyte-6,122.29% -269.32% -59.71% Rezolute N/A -70.27%-62.41% Do insiders & institutionals have more ownership in OCX or RZLT? 55.3% of OncoCyte shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 2.1% of OncoCyte shares are held by insiders. Comparatively, 18.4% of Rezolute shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, OCX or RZLT? OncoCyte has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Does the MarketBeat Community believe in OCX or RZLT? Rezolute received 59 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 79.57% of users gave Rezolute an outperform vote while only 12.82% of users gave OncoCyte an outperform vote. CompanyUnderperformOutperformOncoCyteOutperform Votes1512.82%Underperform Votes10287.18% RezoluteOutperform Votes7479.57% Underperform Votes1920.43% Which has higher valuation and earnings, OCX or RZLT? OncoCyte has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than OncoCyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncoCyte$3.84M20.09-$27.78M-$3.53-0.76RezoluteN/AN/A-$68.46M-$1.15-3.75 Does the media refer more to OCX or RZLT? In the previous week, Rezolute had 1 more articles in the media than OncoCyte. MarketBeat recorded 2 mentions for Rezolute and 1 mentions for OncoCyte. OncoCyte's average media sentiment score of 1.89 beat Rezolute's score of 1.74 indicating that OncoCyte is being referred to more favorably in the media. Company Overall Sentiment OncoCyte Very Positive Rezolute Very Positive Do analysts recommend OCX or RZLT? OncoCyte presently has a consensus target price of $6.06, indicating a potential upside of 124.54%. Rezolute has a consensus target price of $11.83, indicating a potential upside of 174.49%. Given Rezolute's stronger consensus rating and higher possible upside, analysts plainly believe Rezolute is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OncoCyte 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Rezolute 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 SummaryRezolute beats OncoCyte on 13 of the 18 factors compared between the two stocks. Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCX vs. The Competition Export to ExcelMetricOncoCyteDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.22M$2.71B$5.61B$8.62BDividend YieldN/A0.70%5.28%4.17%P/E Ratio-0.767.8427.1419.96Price / Sales20.0934.39414.30157.63Price / CashN/A15.7538.2534.64Price / Book1.095.427.074.69Net Income-$27.78M-$65.73M$3.23B$248.14M7 Day Performance-9.09%-1.36%0.71%0.91%1 Month Performance-2.53%1.68%9.65%5.71%1 Year Performance0.75%-20.05%32.07%14.71% OncoCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCXOncoCyte2.8353 of 5 stars$2.70+2.3%$6.06+124.5%-1.8%$77.22M$3.84M-0.76120Positive NewsRZLTRezolute2.7158 of 5 stars$4.22+2.4%$12.14+187.7%-19.7%$360.89MN/A-3.4640Positive NewsHigh Trading VolumeARCTArcturus Therapeutics3.2482 of 5 stars$12.81+2.2%$53.50+317.6%-59.3%$347.42M$131.27M-5.77180Positive NewsAnalyst RevisionADCTADC Therapeutics2.6417 of 5 stars$3.50+13.3%$7.75+121.3%+15.8%$347.32M$75.82M-1.47310News CoverageAnalyst RevisionHigh Trading VolumeRAPPRapport Therapeutics1.8145 of 5 stars$9.40+13.7%$32.67+247.5%N/A$343.08MN/A-2.72N/APositive NewsHigh Trading VolumeORGOOrganogenesis4.6413 of 5 stars$2.66-2.9%$5.50+106.8%+20.1%$337.43M$458.76M-44.33950Positive NewsAnalyst RevisionSNDLSNDL3.6235 of 5 stars$1.27flat$3.63+185.4%-34.1%$333.73M$927.61M-4.10580IVAInventiva2.1301 of 5 stars$3.39flat$10.40+206.8%+5.3%$324.29M$9.20M0.00100Gap DownPHATPhathom Pharmaceuticals3.9848 of 5 stars$4.64+9.2%$17.60+279.3%-7.7%$323.94M$81.86M-0.82110AURAAura Biosciences2.6987 of 5 stars$6.16+5.1%$22.00+257.1%-7.9%$309.66MN/A-3.5650Positive NewsTRDAEntrada Therapeutics2.9126 of 5 stars$8.14+7.1%$25.67+215.3%-50.6%$308.94M$172.22M5.12110Positive News Related Companies and Tools Related Companies Rezolute Alternatives Arcturus Therapeutics Alternatives ADC Therapeutics Alternatives Rapport Therapeutics Alternatives Organogenesis Alternatives SNDL Alternatives Inventiva Alternatives Phathom Pharmaceuticals Alternatives Aura Biosciences Alternatives Entrada Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
